|
Delayed
Australian S.E.
00:10:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 10.32 AUD | -5.28% |
|
+7.96% | -17.26% |
| Market Cap | 549M 391M 335M 312M 287M 539M 37.41B 3.71B 1.44B 18.75B 1.47B 1.44B 62.07B | P/E 2026 * |
15.4x | P/E 2027 * | 14.6x |
|---|---|---|---|---|---|
| Enterprise Value | 296M 211M 181M 169M 155M 291M 20.2B 2B 780M 10.12B 793M 775M 33.51B | EV / Sales 2026 * |
2.99x | EV / Sales 2027 * | 2.53x |
| Free-Float |
83.79% | Yield 2026 * |
0.56% | Yield 2027 * | 0.73% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -5.33% | ||
| 1 week | +7.96% | ||
| Current month | +13.80% | ||
| 1 month | +2.59% | ||
| 3 months | +11.82% | ||
| 6 months | -8.92% | ||
| Current year | -17.26% |
| 1 week | 9.33 |  | 11.13 |
| 1 month | 8.77 | | 11.13 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 5 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/3/24 | Buy | Director | 8,333 | 0.0166% | ||
| 11/27/23 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 11/27/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.28% | +7.96% | -14.01% | -50.90% | 373M | |
| -1.69% | +2.56% | +39.87% | +1.75% | 83.96B | |
| -23.55% | +109.46% | +395.80% | +31.19% | 69.62B | |
| -2.07% | +22.67% | -25.91% | -37.26% | 56.76B | |
| +1.94% | +0.64% | +0.46% | +32.78% | 51.35B | |
| +0.05% | -0.55% | +11.63% | +170.68% | 48.41B | |
| -3.25% | +1.76% | +54.22% | -17.92% | 32.74B | |
| -0.97% | +5.56% | +47.59% | +98.66% | 26.04B | |
| +2.67% | +10.77% | +4.63% | +233.55% | 21.81B | |
| -0.90% | +2.85% | +62.35% | +125.73% | 17.11B | |
| Average | -1.28% | +15.67% | +57.66% | +58.83% | 40.82B | |
| Weighted average by Cap. | -1.16% | +22.88% | +83.78% | +47.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.21M 70.63M 60.48M 56.43M 51.78M 97.29M 6.76B 669M 261M 3.39B 265M 259M 11.21B | 105M 74.48M 63.77M 59.49M 54.59M 103M 7.13B 706M 275M 3.57B 280M 274M 11.82B |
| Net income | 35.72M 25.43M 21.77M 20.32M 18.64M 35.03M 2.43B 241M 93.95M 1.22B 95.49M 93.41M 4.04B | 37.66M 26.81M 22.96M 21.42M 19.66M 36.93M 2.57B 254M 99.06M 1.29B 101M 98.49M 4.26B |
| Net Debt | -253M -180M -154M -144M -132M -248M -17.21B -1.71B -665M -8.63B -676M -661M -28.56B | -285M -203M -173M -162M -149M -279M -19.39B -1.92B -749M -9.72B -761M -744M -32.17B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-21 | A$10.32 | -5.28% | 69,769 |
| 26-08-20 | A$10.89 | +4.71% | 271,838 |
| 26-08-19 | A$10.40 | +0.39% | 150,545 |
| 26-08-18 | A$10.36 | +5.82% | 208,294 |
| 26-08-17 | A$9.790 | +2.51% | 87,880 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
